Annexin A10 is a novel prognostic biomarker of papillary thyroid cancer

Liu, Xiaoyun; Yang, Meijing; Guo, Yang; Lü, Xiaofei

doi:10.1007/s11845-020-02263-x

Cited by 15 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the most interesting observation was the significance of ANXA10 expression in SBA. Previous reports have shown that ANXA10 is an independent prognostic factor in several carcinomas: hepatocellular carcinoma (12), cholangiocarcinoma (24), ovarian cancer (25), thyroid cancer (26), and early gastric cancers (15). These results suggest that ANXA10 immunostaining is a clinically significant modality to predict survival of SBA patients.…”

Section: Discussionmentioning

confidence: 61%

Annexin A10 Expression Is Associated With Poor Prognosis in Small Bowel Adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

Background/Aim: Small bowel adenocarcinoma (SBA) is a relatively rare malignant epithelial neoplasm. Thus, little is known about prognostic biomarkers of SBA. Annexin A10 (ANXA10) is a member of the annexin family. The significance of ANXA10 expression in SBA is unclear. This is the first study to examine the expression of ANXA10 in SBA. Materials and Methods: We immunohistochemically evaluated ANXA10 expression of SBA and studied the relationship between ANXA10 expression and clinicopathological factors. Results: ANXA10 expression was detected in 17 (56.7%) of 30 SBA cases and was significantly associated with poor overall survival. Univariate predictors for poor prognosis were tumour size (p=0.017) and ANXA10 expression (p=0.026). In multivariate analysis, ANXA10 expression (p=0.038) and tumour size (p=0.024) were found to be independent predictors of poor prognosis. Conclusion: ANXA10 could be a new prognostic biomarker for SBA.

show abstract

Section: Discussionmentioning

confidence: 61%

Annexin A10 Expression Is Associated With Poor Prognosis in Small Bowel Adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In Wang's study, ANXA1 was found to be highly expressed in normal cervical squamous tissue, and its expression was significantly reduced as the tissue morphology changed with the progression of cervical tumors (Wang et al, 2008). Another study by Liu reported that only ANXA10 of the ANXA family proteins was highly expressed in papillary thyroid carcinoma and was related to papillary thyroid carcinoma differentiation and progression (Liu et al, 2021). Interestingly, we found that bladder cancer with high expression of ANXA1 also showed a squamous pattern, FIGURE 7 | Correlation between ANXA and subtype gene expression.…”

Section: Discussionmentioning

confidence: 98%

Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer

Jia

Chen

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

BackgroundBladder cancer (BC) is the most common tumor of the urinary system. Non-muscle-invasive bladder cancer (NMIBC) has a high recurrence rate after surgery, and patients with muscle-invasive bladder cancer (MIBC) have poor quality of life after radical surgery. Understanding the molecular mechanism of bladder cancer is helpful for providing a more appropriate treatment approach. Annexins are calcium-binding proteins and play an important role in different tumor cells. However, the role of the annexin family in bladder cancer has not been studied in detail.MethodsONCOMINE, UALCAN, TIMER2.0, Kaplan-Meier Plotter, cBioPortal, and WebGestalt were utilized in this study.ResultsANXA2, ANXA3, ANXA4, ANXA8, and ANXA9 were significantly increased in bladder tumor tissues, while ANXA6, ANXA7, and ANXA11 were significantly decreased. ANXA1, ANXA2, ANXA3, ANXA5, ANXA6, ANXA7, and ANXA9 had prognostic value in bladder cancer. In addition, specific annexins were specifically expressed in different subtypes of MIBC and were related to the histological morphology of bladder tumors. ANXA1, ANXA2, ANXA3, ANXA5, ANXA6, ANXA7, and ANXA8 were highly expressed in basal-subtype MIBC, while ANXA4, ANXA9, ANXA10, and ANXA11 were mainly expressed in luminal-subtype MIBC. Finally, we analyzed the possible mechanisms of ANXAs in different subtypes of bladder cancer through GO and KEGG analyses and the correlation between ANXAs and immune infiltration in the tumor microenvironment.ConclusionTaken together, our results indicate that annexins might play important roles in BC and have the potential to be used as markers for subtype classification.

show abstract

“…In the present study, Kaplan-Meier analysis demonstrated that the loss of ANXA10 expression correlated with overall survival and served as an independent prognostic classifier of patients with early GC. To date, ANXA10 has been reported as an independent prognostic factor in hepatocellular carcinoma [10], ovarian cancer [21], cholangiocarcinoma [19], and thyroid cancer [11]. Despite various investigations, this is the first report of ANXA10 in earlystage gastric cancer.…”

Section: Discussionmentioning

confidence: 80%

Loss of Annexin A10 Expression Is Associated with Poor Prognosis in Early Gastric Cancer

Ishikawa

Kuraoka

Zaitsu

et al. 2020

Acta Histochem. Cytochem

View full text Add to dashboard Cite

Gastric cancer (GC) is the third most common cause of cancer-related mortality. The diagnosis and treatment of early GC is a crucial strategy for prognostic improvement of GC. Annexin A10 (ANXA10), a calcium-/phospholipid-binding protein, is a member of the annexin family. The significance of ANXA10 expression in early GC remains unclear. This is the first report to investigate ANXA10 expression in early GC. We performed immunohistochemistry to evaluate ANXA10 expression in early GC, and the correlation between ANXA10 and clinicopathological factors. The loss of ANXA10 expression was detected in 63 (61.2%) of 103 early GC cases and significantly correlated with poor overall survival in patients. Sex, pT stage, pN stage, histology, and ANXA10 expression were associated with poor survival. Sex, histology, and ANXA10 expression were determined as independent predictors of survival in early GC patients. ANXA10 immunostaining could be a new decision-making biomarker in GC.

show abstract

Annexin A10 is a novel prognostic biomarker of papillary thyroid cancer

Cited by 15 publications

References 24 publications

Annexin A10 Expression Is Associated With Poor Prognosis in Small Bowel Adenocarcinoma

Annexin A10 Expression Is Associated With Poor Prognosis in Small Bowel Adenocarcinoma

Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer

Loss of Annexin A10 Expression Is Associated with Poor Prognosis in Early Gastric Cancer

Contact Info

Product

Resources

About